AstraZeneca Finds Two More Potential Partners For Imfinzi
Combo Data At ESMO Supports Use With CD73 And NGK2A Inhibitors
Adding oleclumab and monalizumab to the PD-L1 inhibitor improved PFS, while another study showed improved real-world outcomes.
You may also be interested in...
The immunotherapy drugs fall short of the standard set by Keytruda, but could gain some traction in non-squamous patient group.
The French firm gave back the rights to Lumoxiti on the same day the drug got a thumbs up from the CHMP after struggling to market the rare leukemia drug in the US.
Global Head of Oncology Dave Fredrickson took over the commercial leadership role in October. Now he is overseeing several key growth drivers, including Imfinizi and Lynparza, while building out a new hematology franchise. Fredrickson talked with Scrip about AstraZeneca's oncology strategy at ASCO.